SCHEMBL29560845

SCHEMBL29560845

CNc1cccc(-c2nc(Nc3cccc(S(C)(=O)=O)c3)nc(NC(C)C)n2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 5/20 0.52
▸ IDH2 P48735 2/20 0.52
▸ KCNH3 Q9ULD8 3/20 0.44
▸ POLB P06746 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ TNNI3K Q59H18 1/20 0.42
▸ ROCK1 Q13464 1/20 0.42
▸ CDK9 P50750 2/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CCNE1 P24864 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ AURKA O14965 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ MET P08581 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ FGFR1 P11362 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15102250 1.00 IDH1 (0.52) IDH1IDH2KCNH3POLBCA1
SCHEMBL29560403 0.87 IDH1 (0.53) IDH1IDH2KCNH3POLBCA1
SCHEMBL15102435 0.87 IDH1 (0.53) IDH1IDH2KCNH3POLBCA1
SCHEMBL16391816 0.86 TNNI3K (0.47) IDH1IDH2TNNI3KROCK1CDK9
SCHEMBL29561084 0.86 IDH1 (0.53) IDH1IDH2KCNH3POLBCA1
SCHEMBL15102285 0.86 IDH1 (0.53) IDH1IDH2KCNH3POLBCA1
SCHEMBL15102434 0.85 IDH1 (0.71) IDH1IDH2
SCHEMBL29560264 0.85 IDH1 (0.71) IDH1IDH2
SCHEMBL16388189 0.85 ROCK1 (0.51) IDH2TNNI3KROCK1CDK9CCNT1
SCHEMBL15102239 0.84 IDH1 (0.53) IDH1IDH2KCNH3POLBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647076-A2 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier (FR) 2025-11-12 — — EP disclosed
EP-3984997-B1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER LAB (FR) 2025-07-30 — — EP disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 — — US disclosed
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2022-11-03 — — US disclosed
CN-108912066-B Therapeutically active compounds and methods of use thereof 安吉奥斯医药品有限公司 2022-06-24 — — CN disclosed
EP-3984997-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier SAS (FR) 2022-04-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH1 172/4885IDH2 110/4885KCNH3 4722/4885
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH1 172/4885IDH2 110/4885KCNH3 4722/4885
US-11505538-B1 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT IDH1 172/4885IDH2 110/4885KCNH3 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback